This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.

United Kingdom | EN-GB

Cortex - Life Sciences Insights

Marion de Galembert

Associate, DLA Piper

Paris, France

About me

24 Oct, 2024

DLA Piper Genomics Series: Navigating Regulatory Challenges in the Era of Cell and Gene Therapies

By Marion Abecassis Lyndsey Hudson Nicola Landolfi +2 more...

As healthcare moves towards personalised and precision medicine,[2] cell and gene therapies (CGTs) have emerged as cutting-edge and...

24 May, 2022

Raw material shortage and its impact on the pharma industry

By Sonia de Kondserovsky Marion Abecassis Marion de Galembert

The COVID-19 pandemic, followed by the Ukraine war, has led to an economic crisis that has resulted in supply difficulties and a sharp...

18 Feb, 2022

A new chapter in France's CBD legal saga

By Marion Abecassis Marion de Galembert

In an expected order of 24 January 2022, the interim relief judge of the French Administrative Supreme Court (Conseil d’Etat – “CE”)...

DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper's structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.